$BCTX announces peer-reviewed validation of its Bria-OTS+™ immunotherapy in JCI Insight. Backed by NCI data, the study highlights Bria-OTS+ cancer-killing potential and its role in addressing urgent unmet needs in oncology:
https://globenewswire.com/news-release/2025/0...urnal.html